Pharma
OpinionBY
- By embedding children’s needs more explicitly within regulatory decision-making, we can ensure that medicines proven safe and effective in comparable jurisdictions can reach Canada’s kids faster.
OpinionBY
- By embedding children’s needs more explicitly within regulatory decision-making, we can ensure that medicines proven safe and effective in comparable jurisdictions can reach Canada’s kids faster.
- Seven provinces and two territories don’t yet have deals even though Prime Minister Mark Carney said last fall that his government is committed to
- Seven provinces and two territories don’t yet have deals even though Prime Minister Mark Carney said last fall that his government is committed to
- Seven provinces and two territories don’t yet have deals even though Prime Minister Mark Carney said last fall that his government is committed to
- Only British Columbia, Manitoba, Prince Edward Island, and the Yukon have reached pharmacare deals with the federal government, covering contraception and diabetes medications.
- Only British Columbia, Manitoba, Prince Edward Island, and the Yukon have reached pharmacare deals with the federal government, covering contraception and diabetes medications.
- Only British Columbia, Manitoba, Prince Edward Island, and the Yukon have reached pharmacare deals with the federal government, covering contraception and diabetes medications.
- The agency’s 2024-25 departmental results report uses rates from a 2021 survey. Newer data is available, but that source doesn’t include rates from all
- The agency’s 2024-25 departmental results report uses rates from a 2021 survey. Newer data is available, but that source doesn’t include rates from all
- The agency’s 2024-25 departmental results report uses rates from a 2021 survey. Newer data is available, but that source doesn’t include rates from all
- But that doesn’t mean the drug pricing tribunal can’t look at past years’ data to inform future reviews of drug prices, says director general
- But that doesn’t mean the drug pricing tribunal can’t look at past years’ data to inform future reviews of drug prices, says director general
- But that doesn’t mean the drug pricing tribunal can’t look at past years’ data to inform future reviews of drug prices, says director general
- Interim NDP leader Don Davies says the feds must continue negotiating deals with provinces and territories under the pharmacare law passed last year.
- Interim NDP leader Don Davies says the feds must continue negotiating deals with provinces and territories under the pharmacare law passed last year.
- Interim NDP leader Don Davies says the feds must continue negotiating deals with provinces and territories under the pharmacare law passed last year.
- The big news in health care these days is national pharmacare. This is surely welcome news for those of us living with any chronic
- The big news in health care these days is national pharmacare. This is surely welcome news for those of us living with any chronic
- The big news in health care these days is national pharmacare. This is surely welcome news for those of us living with any chronic
- Focusing on a list of the most commonly prescribed clinically-important drugs could save billions of dollars, both directly in terms of drug budget, and
- Focusing on a list of the most commonly prescribed clinically-important drugs could save billions of dollars, both directly in terms of drug budget, and
- Focusing on a list of the most commonly prescribed clinically-important drugs could save billions of dollars, both directly in terms of drug budget, and
- Pharmacare is the most innovative and important health policy legislation in decades. To get it right, the federal government must directly engage with patients.
- Pharmacare is the most innovative and important health policy legislation in decades. To get it right, the federal government must directly engage with patients.
- Pharmacare is the most innovative and important health policy legislation in decades. To get it right, the federal government must directly engage with patients.
- Green Party Leader Elizabeth May and NDP Leader Jagmeet Singh have done their part as responsible opposition critics on this policy. Now it’s Pierre
- Green Party Leader Elizabeth May and NDP Leader Jagmeet Singh have done their part as responsible opposition critics on this policy. Now it’s Pierre
- Green Party Leader Elizabeth May and NDP Leader Jagmeet Singh have done their part as responsible opposition critics on this policy. Now it’s Pierre
- Canadians have the chance to consider whether to view access to medicines as a pillar of healthcare, or simply an add-on service.
- Canadians have the chance to consider whether to view access to medicines as a pillar of healthcare, or simply an add-on service.
- Canadians have the chance to consider whether to view access to medicines as a pillar of healthcare, or simply an add-on service.
- Re: “First phase of pharmacare must not ‘create new gaps’ in existing coverage, says lobbyists (The Hill Times, April 1). I strongly endorse the
Opinion | April 8, 2024
Opinion | April 8, 2024
- Re: “First phase of pharmacare must not ‘create new gaps’ in existing coverage, says lobbyists (The Hill Times, April 1). I strongly endorse the
Opinion | April 8, 2024
- Re: “First phase of pharmacare must not ‘create new gaps’ in existing coverage, says lobbyists (The Hill Times, April 1). I strongly endorse the
- Using insulin is always challenging, so access to a broad range of appropriate options is vital.
- Using insulin is always challenging, so access to a broad range of appropriate options is vital.
- Using insulin is always challenging, so access to a broad range of appropriate options is vital.
- Bill C-64 outlines a proposed first phase towards implementation of national universal pharmacare to address accessibility and affordability of prescription drugs and related products.
- Bill C-64 outlines a proposed first phase towards implementation of national universal pharmacare to address accessibility and affordability of prescription drugs and related products.
- Bill C-64 outlines a proposed first phase towards implementation of national universal pharmacare to address accessibility and affordability of prescription drugs and related products.
- The proposed new law would likely prohibit Canadians from purchasing supplemental insurance to cover drugs not covered (or only partially covered) by pharmacare.
- The proposed new law would likely prohibit Canadians from purchasing supplemental insurance to cover drugs not covered (or only partially covered) by pharmacare.
- The proposed new law would likely prohibit Canadians from purchasing supplemental insurance to cover drugs not covered (or only partially covered) by pharmacare.
- The government will likely need to borrow to finance any new spending and add more debt, which will result in higher taxes in the
- The government will likely need to borrow to finance any new spending and add more debt, which will result in higher taxes in the
- The government will likely need to borrow to finance any new spending and add more debt, which will result in higher taxes in the
- Florida’s plan is designed to relieve pressure on an already overburdened government health-care system, and will bring tens, if not hundreds, of millions of
- Florida’s plan is designed to relieve pressure on an already overburdened government health-care system, and will bring tens, if not hundreds, of millions of
- Florida’s plan is designed to relieve pressure on an already overburdened government health-care system, and will bring tens, if not hundreds, of millions of
- The FDA’s Florida decision might wind up limiting Canadians’ access to pharmaceutical medicines as long as Canadian drug prices remain well below prices in
- The FDA’s Florida decision might wind up limiting Canadians’ access to pharmaceutical medicines as long as Canadian drug prices remain well below prices in
- The FDA’s Florida decision might wind up limiting Canadians’ access to pharmaceutical medicines as long as Canadian drug prices remain well below prices in
